{"product_id":"abbott-marketing-mix","title":"Abbott Laboratories Marketing Mix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGet Inspired by a Complete Brand Strategy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eAbbott Laboratories leverages a diversified product portfolio, competitive pricing tiers, global distribution channels, and targeted promotional strategies to sustain market leadership in healthcare and diagnostics; discover how these elements interlock to drive growth. Get the full 4P's Marketing Mix Analysis in an editable, presentation-ready format—professionally researched and perfect for benchmarking, strategy, or coursework.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eroduct\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMedical Device Innovation and Digital Health\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAbbott’s FreeStyle Libre franchise, with advanced biosensing added in late 2025, drove a 2025 revenue of about $2.1B in glucose monitoring, up 12% YoY, and now extends into metabolic and athletic sensing.\u003c\/p\u003e\n\u003cp\u003eDevices deliver real-time metabolic data and pair with AI platforms; Abbott reported 6.3M active users worldwide in 2025 and reduced clinician review time by ~40% in pilot studies.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDiagnostic Solutions and Rapid Testing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAbbott holds a leading diagnostics share via the Alinity systems, which processed over 150 million tests in 2024 and serve 1,200+ hospitals globally; Alinity delivers high-throughput lab automation and 98% uptime in clinical settings.\u003c\/p\u003e\n\u003cp\u003eBy 2025 Abbott expanded point-of-care (POC) tools for rapid detection of respiratory viruses and chronic markers, cutting time-to-result to 15–20 minutes and enabling testing in pharmacies and remote clinics.\u003c\/p\u003e\n\u003cp\u003eProducts scale from 10 tests\/day bench units to Alinity platforms handling 2,000+ tests\/day, supporting large urban centers and low-resource sites while contributing roughly $6.2 billion to Abbott’s 2024 diagnostics revenue.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNutritional Products for All Life Stages\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAbbott’s nutrition line—Similac, Ensure, Glucerna—generated roughly $8.4 billion in 2024 revenue, leading infant and adult nutrition markets; Similac holds ~28% U.S. infant formula share (2024). \u003c\/p\u003e\n\u003cp\u003eBy end-2025 Abbott emphasized specialized medical nutrition for surgical recovery and metabolic care, launching \u0026gt;10 formula updates and claiming 12% CAGR in that segment since 2021. \u003c\/p\u003e\n\u003cp\u003ePackaging and formulations update annually to reflect pediatric and geriatric research; R\u0026amp;D spend for nutrition was about $420 million in 2024 to support those changes. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEstablished Pharmaceuticals in Emerging Markets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAbbott Laboratories established pharmaceuticals unit sells branded generics across Asia, Latin America and Africa, focusing on high-growth markets where Abbott reported emerging-market revenues of $7.2 billion in 2024; the division adapts existing therapies rather than discovering new molecules.\u003c\/p\u003e\n\u003cp\u003eIt ensures regulatory-compliant quality and steady supply chains, serving gastroenterology, women’s health and cardiovascular portfolios that together accounted for roughly 18% of Abbott’s 2024 pharma sales.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eBranded generics focus\u003c\/li\u003e\n\u003cli\u003eMarkets: Asia, LATAM, Africa\u003c\/li\u003e\n\u003cli\u003e2024 emerging-market revenue $7.2B\u003c\/li\u003e\n\u003cli\u003eTherapies: GI, women’s health, CV\u003c\/li\u003e\n\u003cli\u003eNo novel R\u0026amp;D; optimize existing drugs\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCardiovascular and Neuromodulation Technologies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAbbott sells structural heart devices like MitraClip and rhythm-management pacemakers\/defibrillators; cardiac devices drove about $7.2B of Abbott’s $43.1B revenue in 2024, with 2025 strategy pushing minimally invasive tech to cut hospital stays by ~30% and improve outcomes.\u003c\/p\u003e\n\u003cp\u003eThe neuromodulation unit offers implanted pulse generators for chronic pain and movement disorders, targeting a market CAGR near 6% and aiming to raise device uptake via outpatient implants and remote-programming features.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 cardiac revenue ~$7.2B\u003c\/li\u003e\n\u003cli\u003e2025 push: minimally invasive → ~30% shorter stays\u003c\/li\u003e\n\u003cli\u003eNeuromodulation market CAGR ~6%\u003c\/li\u003e\n\u003cli\u003eFocus: outpatient implants, remote programming\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAbbott: Diverse $—8.4B Nutrition, $2.1B Libre, $7.2B Cardiac \u0026amp; 150M Alinity tests\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAbbott’s product portfolio spans FreeStyle Libre (6.3M users, $2.1B glucose revenue 2025), Alinity diagnostics (150M tests 2024; 1,200+ hospitals), POC rapid tests (15–20 min), nutrition (Similac\/Ensure $8.4B 2024; Similac 28% US), emerging-market branded generics ($7.2B 2024), cardiac devices ($7.2B 2024) and growing neuromodulation (≈6% CAGR).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003eKey metric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eLibre\u003c\/td\u003e\n\u003ctd\u003e$2.1B; 6.3M users (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAlinity\u003c\/td\u003e\n\u003ctd\u003e150M tests (2024); 1,200+ hospitals\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNutrition\u003c\/td\u003e\n\u003ctd\u003e$8.4B (2024); Similac 28% US\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCardiac\u003c\/td\u003e\n\u003ctd\u003e$7.2B (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eDelivers a concise, company-specific deep dive into Abbott Laboratories’ Product, Price, Place, and Promotion strategies, using real brand practices and competitive context to ground insights for managers, consultants, and marketers.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eCondenses Abbott Laboratories’ 4P marketing strategy into a concise, leadership-ready snapshot that highlights product innovation, pricing strategy, distribution channels, and promotion tactics to quickly align stakeholders and drive marketing decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003elace\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Multi-Channel Distribution Network\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAbbott operates a logistics network across 160+ countries, delivering diagnostics and devices to hospitals and clinics; in 2024 global revenues from diagnostics and devices were about $18.5 billion, underscoring distribution scale.\u003c\/p\u003e\n\u003cp\u003eThe company uses direct sales for high-tech systems like Alinity and third-party distributors for consumer products such as Ensure and FreeStyle; direct channels account for roughly 40% of device sales.\u003c\/p\u003e\n\u003cp\u003eBy end-2025 Abbott shifted toward localized supply chains, cutting transoceanic freight exposure by ~30% and targeting a 12% reduction in distribution-related CO2 vs 2022 levels to lower disruption risk and emissions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Healthcare Provider Partnerships\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cpa significant portion of abbott diagnostics revenue comes from direct contracts with hospital systems clinical labs and government health departments in reported billion institutional placements driving roughly that figure. these often include multi-year equipment leases which seed recurring consumables sales cartridges accounted for about gross margin by locking major medical centers into platform ecosystems devices form the backbone decision-making supporting steady annuity-like higher lifetime customer value.\u003e\n\u003c\/pa\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRetail and E-commerce Integration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAbbott places consumer products like Ensure nutritional shakes and BinaxNOW over-the-counter tests across pharmacies, supermarkets, and big-box retailers, driving retail penetration in 150+ countries and retail sales that contributed to roughly $11.5B of consumer segment revenue in 2024.\u003c\/p\u003e\n\u003cp\u003eBy 2025 Abbott expanded e-commerce through direct-to-consumer sites and Amazon, Walmart.com, and Alibaba listings, with digital sales growing double digits year-over-year and representing an estimated 12–15% of consumer revenue.\u003c\/p\u003e\n\u003cp\u003eThis omnichannel mix supports subscription models for chronic-care nutrition and glucose-monitoring supplies, improving retention—monthly reorder rates rose ~20% for subscription customers—and boosting lifetime value while lowering distribution costs. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDirect-to-Patient Distribution Channels\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eAbbott ships FreeStyle Libre sensors direct to patients after insurer authorization, removing retail delays and reducing refill gaps; in 2024 Abbott reported over 4.5 million treated patients globally for its continuous glucose monitoring (CGM) franchise.\u003c\/p\u003e\n\u003cp\u003eControlling fulfillment lets Abbott provide onboarding, firmware\/software updates, and targeted support, improving adherence and generating higher lifetime revenue per patient—Libre subscription revenue rose ~18% in 2024 to roughly $2.1 billion.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eDirect-to-patient reduces supply gaps and retail friction\u003c\/li\u003e\n\u003cli\u003e4.5M+ patients using Libre (2024)\u003c\/li\u003e\n\u003cli\u003eSubscription revenue +18% to ~$2.1B (2024)\u003c\/li\u003e\n\u003cli\u003eCloser user engagement enables updates and support\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEmerging Market Localization\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cpabbott uses localized manufacturing and distribution in emerging markets to cut costs meet complex regulations with revenues from international at about billion of total sales showing the strategy scale.\u003e\n\u003cpplacing plants near demand lets abbott respond faster to outbreaks and swings after expanding sites in india mexico regional supply lead times fell by\u003e\n\u003cpthis footprint drives growth where healthcare spending rose cagr helping abbott gain market share in diagnostics and nutrition segments.\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e45% of 2024 sales from international markets\u003c\/li\u003e\n\u003cli\u003e~30% shorter regional lead times after 2023–24 expansions\u003c\/li\u003e\n\u003cli\u003e6% CAGR regional healthcare spending 2019–24\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pthis\u003e\u003c\/pplacing\u003e\u003c\/pabbott\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAbbott: $24B+ revenue, 4.5M Libre users, $2.1B subscription and 45% intl sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAbbott’s place strategy combines direct sales for high-tech systems and DTC fulfillment (4.5M+ Libre patients; Libre subscription revenue ~$2.1B in 2024), third-party distributors for consumer lines (consumer revenue ~$11.5B in 2024), localized manufacturing reducing lead times ~30% and international sales ~45% of 2024 revenue; digital channels ~12–15% of consumer sales.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eDiagnostics revenue\u003c\/td\u003e\n\u003ctd\u003e$12.4B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eConsumer revenue\u003c\/td\u003e\n\u003ctd\u003e$11.5B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLibre patients\u003c\/td\u003e\n\u003ctd\u003e4.5M+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLibre sub rev\u003c\/td\u003e\n\u003ctd\u003e$2.1B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIntl sales %\u003c\/td\u003e\n\u003ctd\u003e45%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDigital consumer %\u003c\/td\u003e\n\u003ctd\u003e12–15%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Version Awaits\u003c\/span\u003e\u003cbr\u003eAbbott Laboratories 4P's Marketing Mix Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the actual Abbott Laboratories 4P's Marketing Mix analysis you’ll receive instantly after purchase—comprehensive, editable, and ready to use with no surprises.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56750431502713,"sku":"abbott-marketing-mix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/abbott-marketing-mix.png?v=1772224915","url":"https:\/\/matrixbcg.com\/products\/abbott-marketing-mix","provider":"MatrixBCG","version":"1.0","type":"link"}